Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Compound heterozygosity for two non-synonymous polymorphisms in NPC1L1 in a non-responder to ezetimibe.

Clinical genetics - 1 Feb 2005

Wang J, Williams C M, Hegele R A

Abstract excerpt

Ezetimibe reduces plasma low-density lipoprotein (LDL) cholesterol by blocking sterol absorption in enterocytes. The NPC1L1 gene product was recently identified as the molecular target for ezetimibe, although functional details are incomplete. We used the non-response phenotype of plasma LDL cholesterol to ezetimibe treatment to ascertain individuals who might have variant NPC1L1. We found that one non-responder...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anticholesteremic Agents
Share to Azetidines
Share to Drug Resistance

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Ezetimibe

Share to Hyperlipidemias

Share to Membrane Proteins

Share to Membrane Transport Proteins

Share to Proteins

Source

Identifiers

PMID: 15679830
DOI: 10.1111/j.1399-0004.2004.00388.x

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Compound heterozygosity for two non-synonymous polymorphisms in NPC1L1 in a non-responder to ezetimibe.PMID 15679830Read ↗

Sequence variation in NPC1L1 and association with improved LDL-cholesterol lowering in response to ezetimibe treatment.Semantic proximity Read ↗

Characterization of the NPC1L1 gene and proteome from an exceptional responder to ezetimibe.Semantic proximity Read ↗

NPC1L1 haplotype is associated with inter-individual variation in plasma low-density lipoprotein response to ezetimibe.Semantic proximity Read ↗

In-vitro characterization of the six clustered variants of NPC1L1 observed in cholesterol low absorbers.Semantic proximity Read ↗

Using genetics to explore whether the cholesterol-lowering drug ezetimibe may cause an increased risk of cancer.Semantic proximity Read ↗

Inactivating mutations in NPC1L1 and protection from coronary heart disease.Semantic proximity Read ↗

Gene polymorphism and frequencies of the NPC1L1 gene (rs2072183, rs217434 and rs217428) in Japanese patients with dyslipidemia.Semantic proximity Read ↗

NPC1L1: evolution from pharmacological target to physiological sterol transporter.Semantic proximity Read ↗

Efficacy of ezetimibe is not related to NPC1L1 gene polymorphisms in a pilot study of Chilean hypercholesterolemic subjects.Semantic proximity Read ↗

A SNP of NPC1L1 affects cholesterol absorption in Japanese.Semantic proximity Read ↗

The c.-133A > G polymorphism in NPC1L1 gene influences the efficacy of ezetimibe monotherapy on apolipoprotein A1 in hyperlipidemic patients.Semantic proximity Read ↗

Multiple rare variants in NPC1L1 associated with reduced sterol absorption and plasma low-density lipoprotein levels.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.